Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
The use of adenoviral vectors for gene therapy has been limited due to host immune responses directed toward the vector and/or transgene and vector toxicity. To decrease adenoviral vector immunogenicity and toxicity, we attenuated viral gene expression by eliminating E1, E2a, E3, and E4 early genes from the adenoviral backbone. Two highly attenuated, fourth-generation (Av4) E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII (FVIII) under the control of a liver-specific albumin promoter were generated. One Av4 vector (Av4DeltaE4FVIII) was deficient in the entire E4 coding region and the second vector contained a deletion of the E4 region, except for open reading frame 3 (orf 3; Av4orf3FVIII). The Av4 vectors were compared to an E1/E2a/E3-deficient third-generation vector (Av3H8101) containing an analogous transgene expression cassette in vitro and in vivo following intravenous administration in hemophiliac mice. In vitro transduction of Hep3B cells revealed at all three vectors expressed functional FVIII. However, the Av4DeltaE4FVIII vector could not be scaled-up for in vivo studies. Both Av3H8101 and Av4orf3FVIII initially expressed similar levels of FVIII in hemophiliac mice. However, at 3 months, animals treated with the Av4orf3FVIII vector no longer expressed FVIII while Av3H8101-treated mice displayed persistent FVIII expression. Liver enzyme analyses of plasma samples revealed that the Av4orf3FVIII vector was significantly less hepatotoxic than the Av3H8101 vector. These data demonstrate that further attenuation of the adenoviral vector backbone by removal of the majority of the E4 coding region significantly diminished vector toxicity; however, the duration of transgene expression was reduced.
Genetic Therapy, Inc. (A Novartis Company), 9 West Watkins Mill Road, Gaithersburg, Maryland 20878, USA.
J L
JL
Andrews
M J
MJ
Kadan
M I
MI
Gorziglia
M
M
Kaleko
S
S
Connelly
D017498:Adenovirus E1 Proteins / Q000235:genetics*; D017502:Adenovirus E2 Proteins / Q000235:genetics*; D017503:Adenovirus E3 Proteins / Q000235:genetics*; D017504:Adenovirus E4 Proteins / Q000235:genetics*; D000260:Adenoviruses, Human / Q000235:genetics*; D000818:Animals; D018929:Cell Culture Techniques; D003001:Cloning, Molecular; D005169:Factor VIII / Q000235:genetics*; D017353:Gene Deletion; D015870:Gene Expression; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000302:isolation & purification; D006467:Hemophilia A / Q000628:therapy; D006801:Humans; D008099:Liver / Q000201:enzymology / Q000378:metabolism; D051379:Mice; D011401:Promoter Regions, Genetic; D011995:Recombination, Genetic
D017498:Adenovirus E1 Proteins; D017502:Adenovirus E2 Proteins; D017503:Adenovirus E3 Proteins; D017504:Adenovirus E4 Proteins; D005169:Factor VIII